Q3 2024 Trinity Biotech PLC Earnings Call Transcript
Key Points
- Trinity Biotech PLC (TRIB) reported a 3% year-on-year revenue growth, driven by TrinScreen HIV revenues.
- The company is making significant progress in the development of its next-generation continuous glucose monitor (CGM) for diabetes management, targeting a rapidly growing market.
- Trinity Biotech PLC (TRIB) has successfully addressed NASDAQ listing deficiencies, removing an important overhang from its stock.
- The company is executing a comprehensive transformation plan aimed at enhancing profitability and operational efficiency.
- Trinity Biotech PLC (TRIB) has made strategic acquisitions in innovative prostate cancer and preeclampsia test technologies, expanding its product pipeline.
- TrinScreen HIV revenues were lower in Q3 compared to Q2 due to different ordering patterns, although higher revenues are expected in Q4.
- Hemoglobin revenues from A1c testing products were lower than the previous year due to uneven ordering patterns.
- The company reported an operating loss of $2.6 million in the quarter, although this was an improvement from the previous year's loss.
- Trinity Biotech PLC (TRIB) experienced a decrease in cash balance from $5.3 million to $2.8 million by the end of September.
- The commercialization timeline for newly acquired lab-based technologies, such as the preeclampsia and prostate cancer tests, extends into 2025 and 2026, delaying potential revenue generation.
Greetings. Welcome to Trinity Biotech's third-quarter 2024 earnings conference call. (Operator instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce Eric Ribner, Investor Relations. Thank you, Eric, you may begin.
Thanks very much. Before we begin, please note that statements made during this presentation may be deemed forward-looking statements within the meaning of Federal Securities Laws. These statements are subject to known and unknown risks and uncertainties that may cause actual events to differ from those expressed or implied in such statements.
These risks include, but are not limited to those set forth in the risk factor statement in the company's annual report on Form 20-F filed with the SEC. Trinity Biotech undertakes no obligations to publicly update or revise these forward-looking statements to reflect events or circumstances after today or the occurrence of unanticipated events.
I will now hand you over to John Gillard,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
